MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on January 16, 2018, 12:02:41 pm

Title: Rituxan (rituximab)
Post by: agate on January 16, 2018, 12:02:41 pm
From Multiple Sclerosis News Today, January 16, 2018--"Long-term Rituxan Treatment Is Safe and Effective in MS, Study Shows":


https://multiplesclerosisnewstoday.com/2018/01/16/study-shows-long-term-use-of-rituximab-is-safe-and-effective-for-ms/?utm_source=Multiple+Sclerosis&utm_campaign=58d203277a-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-58d203277a-71286581
Title: Disability progression reduced among SPMS patients taking Rituxan
Post by: agate on January 07, 2019, 11:49:19 am
From JAMA Neurology (January 7, 2019)--this is a link to the entire article, entitled "Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis":


https://jamanetwork.com/journals/jamaneurology/fullarticle/2719699?guestAccessKey=17fb9684-d054-4bd4-a067-c9e3bb1b9462&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=010719

Title: (Abst.) Rituximab vs. placebo induction prior to glatiramer acetate monotherapy in MS
Post by: agate on January 13, 2019, 03:30:50 pm
This small study found that patients treated with rituximab before switching to glatiramer acetate (Copaxone) were more likely to show NEDA (no evidence of disease activity) than patients who received placebo before the change to Copaxone. From PubMed, January 13, 2019:


https://www.ncbi.nlm.nih.gov/pubmed/30635477


Apparently the patients received 2 infusions of Rituxan before starting daily Copaxone injections (from ClinicalTrials.gov Identifier: NCT01569451).

Quote
Active Comparator: (Placebo and) Glatiramer Acetate
Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.


Experimental: Rituximab and Glatiramer Acetate (R-GA)
Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
Title: (Abst.) Rituximab treatment for MS
Post by: agate on June 27, 2019, 03:50:11 pm
More in support of rituximab for treatment of both RRMS and "progressive MS phenotypes," from PubMed (June 27, 2018):


https://www.ncbi.nlm.nih.gov/pubmed/31237800
Title: Aggressive MS in child dramatically resolved w/rituximab treatment, case study reports
Post by: agate on August 25, 2019, 06:08:46 am
From Multiple Sclerosis News Today (August 23, 2019)--"Aggressive MS in Child Dramatically Resolved with Rituximab Treatment, Case Study Reports":


http://bit.ly/2LdNgDM